Bromfenac

Bromfenac
Clinical data
Trade names	Bromday, Prolensa (US), Yellox (EU)
AHFS/Drugs.com	Monograph
MedlinePlus	a611018
License data	US DailyMed: Bromfenac;
Routes of; administration	Eye drops
ATC code	S01BC11 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	99.8%
Metabolism	CYP2C9
Metabolites	Lactam, others
Elimination half-life	1.4 hours in aqueous humour
Excretion	82% urine, 13% faeces
Identifiers
	IUPAC name 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid;
CAS Number	91714-94-2 ;
PubChem CID	60726;
IUPHAR/BPS	7131;
DrugBank	DB00963 ;
ChemSpider	54730 ;
UNII	864P0921DW;
KEGG	D07541 ; as salt: D03163 ;
ChEBI	CHEBI:240107 ;
ChEMBL	ChEMBL1077 ;
CompTox Dashboard (EPA)	DTXSID7040655 ;
Chemical and physical data
Formula	C15H12BrNO3
Molar mass	334.169 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	284 to 286 °C (543 to 547 °F) (bromfenac sodium·1.5H2O)
	SMILES O=C(c1ccc(Br)cc1)c2cccc(c2N)CC(=O)O;
	InChI InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19) ; Key:ZBPLOVFIXSTCRZ-UHFFFAOYSA-N ;
	(verify)

Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID)^[2] marketed in the US as an ophthalmic solution (brand names Prolensa and Bromday,^[3] prior formulation brand name Xibrom, which has since been discontinued) by ISTA Pharmaceuticals for short-term, local use. Prolensa and Bromday are the once-daily formulation of bromfenac, while Xibrom was approved for twice-daily administration. In the European Union, the brand name is Yellox. Bromfenac is indicated for the treatment of ocular inflammation and pain after cataract surgery.^[4]

^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^ Rovere G, Nadal-Nicolás FM, Sobrado-Calvo P, García-Bernal D, Villegas-Pérez MP, Vidal-Sanz M, et al. (November 2016). "Topical Treatment With Bromfenac Reduces Retinal Gliosis and Inflammation After Optic Nerve Crush". Investigative Ophthalmology & Visual Science. 57 (14): 6098–6106. doi:10.1167/iovs.16-20425. PMID 27832276.
^ "Bromfenac Sodium Monograph for Professionals". Drugs.com. 21 April 2020. Retrieved 23 November 2020.
^ Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.

[1] "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.

[2] Rovere G, Nadal-Nicolás FM, Sobrado-Calvo P, García-Bernal D, Villegas-Pérez MP, Vidal-Sanz M, et al. (November 2016). "Topical Treatment With Bromfenac Reduces Retinal Gliosis and Inflammation After Optic Nerve Crush". Investigative Ophthalmology & Visual Science. 57 (14): 6098–6106. doi:10.1167/iovs.16-20425. PMID 27832276.

[Drugs.com-3] "Bromfenac Sodium Monograph for Professionals". Drugs.com. 21 April 2020. Retrieved 23 November 2020.

[AC-4] Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.

[1]

[2]

[3]

[4]